Global Antimicrobial Susceptibility Testing Market Assessment, By Product [Manual Antimicrobial Susceptibility Testing Product, Automated Laboratory Instruments, Culture and Growth Media, Consumables], By Type [Antibacterial Susceptibility Testing, Antifungal Susceptibility Testing, Antiparasitic Susceptibility Testing, Other Susceptibility Testing], By Application [Clinical Diagnostics, Drug Discovery and Development, Epidemiology, Others], By End-user [Hospitals, Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Clinical Research Organizations, Others], By Region, Opportunities and Forecast, 2017-2031F

Antimicrobial Susceptibility Testing Market is projected to witness a CAGR of 6.07% during the forecast period 2024-2031, growing from USD 4.01 billion in 2023 to USD 6.43 billion in 2031.

Antimicrobial Susceptibility Testing Market Size, Share & Report 2031

Global antimicrobial susceptibility testing market&nbsp;is projected to witness a&nbsp;CAGR of 6.07%&nbsp;during the forecast period 2024-2031, growing from&nbsp;USD 4.01 billion&nbsp;in 2023 to&nbsp;USD 6.43 billion&nbsp;in 2031. The antimicrobial susceptibility testing market is an important part of clinical diagnostics industry, accounting for one of the fastest growth rates in the healthcare industry. Factors are driving the market such as growing prevalence of infectious diseases, rising microbial resistance, technological advancements, and government initiatives.
In clinical laboratories, antimicrobial susceptibility tests (ASTs) are used to identify which antibiotics or other antimicrobial medicines are expected to be successful against a certain microbe causing an illness and what dose is required to be effective. These tests are performed with the help&nbsp;of different&nbsp;medical devices used for antimicrobial susceptibility tests. The FDA's Center for Devices and Radiological Health (CDRH) must examine and approve any AST devices before they may be marketed in the United States for use in clinical labs. A number of fast diagnostic tests are available to identify genetic information, or resistance indicators linked to bacteria that are resistant to antibiotics, in addition to traditional ASTs. CDRH examines and approves these tests when microorganisms&nbsp;adapt over time and stop responding to medications, it's known as antimicrobial resistance, or antimicrobial resistance (AMR). The Centers for Disease Control and Prevention (CDC) estimate that over 35,000 individuals lose their lives to antimicrobial-resistant illnesses each year, which account for at least 2.8 million infections in the United States annually.
The UN views AMR as a worldwide threat and issues a warning by 2050, wherein drug-resistant illnesses might claim 10 million lives annually. Antimicrobial resistance may push up to 24 million people into severe poverty by 2030, according to the United Nations&nbsp;estimates.
<h2 style="text-align: justify;">Growing Prevalence of Infectious Diseases</h2>
The growing incidence of infectious diseases is one of the key factors driving the demand for antimicrobial susceptibility testing market. The increasing rate of infections caused by bacteria, fungi, and viruses around the world has necessitated more effective treatment through antibiotics. The identification and treatment of these diseases relies heavily on AST which shows how different types of pathogens response to different kinds of antibiotics. Antibiotic susceptibility testing helps doctors to prescribe effective treatments by identifying the right antimicrobial therapy, thus reducing the likelihood of resistance to antimicrobials, improving patient outcomes. Since infectious diseases are becoming more common, the demand for fast and accurate ASTs has increased significantly due to the development and distribution of new diagnostic tests for infectious diseases.
As per HIV.gov in 2022, there were more than 39 million patients globally. Out of which, 37.5 million were adults and 1.5 million were children. WHO estimates that close to 25% of the global population i.e 1.8 billion people have tuberculosis.
<h2 style="text-align: justify;">Government Initiatives to Support the Global AST Market</h2>
Government funding and government initiatives are playing an important role in supporting and increasing the adoption of antimicrobial susceptibility testing kits and devices. Regulatory agencies such as the FDA (Food and Drug Administration) in the United States have issued guidance and necessary steps to help animal drugs sponsors establish defined duration of use for certain medically important antimicrobial drugs, supporting the appropriate drug usage and growing need for antimicrobial susceptibility testing. Additionally, the FDA has funded R&amp;D initiatives through programs such as Broad Agency Announcement for supporting regulatory science and innovation in antimicrobial resistance. Government-funded partnerships, such as CARB-X, provide funding and support for early-stage projects focused towards new antibiotics, diagnostics, and other technologies to fight against drug-resistant bacteria. In March 2024, CARB-X announced its 100th&nbsp;project funding for addressing antibiotic resistance. CARB-X granted USD 1.06 million to Germany-based company named HIPS for the development of new class of small-molecule inhibitors.
<h2 style="text-align: justify;">Drug Discovery and Development is Expected to Grow at the Fastest Rate in the Forecast Period</h2>
Drug discovery and development will grow at a fast pace in the upcoming years in the global antimicrobial susceptibility testing market. Testing the antibiotic susceptibility of notable bacterial isolates is an essential function of the clinical microbiology lab. Testing ensures the susceptibility of the recommended medication for a disease&nbsp;and the identification of potential drug resistance in living&nbsp;organisms. Once the bacteria or fungi causing an individual's infection are collected in the sample culture, the susceptibility testing is carried upon it. Drug susceptibility testing can be carried out utilizing nucleic acid-based techniques, semiquantitative approaches, or qualitative methods.
At ESCMID 2024 (European Society of Clinical Microbiology and Infectious Disease), several advancements in drug resistance testing were announced, such as rapid nanomotion-based susceptibility testing and MALDI-TOF-MS could be used to identify resistance mechanisms of several deadly organisms. The conference discussed different types of novel resistance testing technologies such as machine learning models, and matrix-assisted laser desorption ionization time-of-flight mass spectrometry.
<a href="https://www.marketsandata.com/industry-reports/antimicrobial-susceptibility-testing-market/sample-request">Download Free Sample Report</a>
<h2 style="text-align: justify;">North America Dominates the Global Antimicrobial Susceptibility Testing&nbsp;Market</h2>
North America dominated the share of the global antimicrobial susceptibility testing market in 2023, and is expected to maintain the dominance in the forecast period. High prevalence of infectious diseases and growing burden of antibiotic resistance in countries such as the United States, Canada, and Mexico are some major drivers. The United States and Canada have advanced healthcare technologies and infrastructure couple with high healthcare spending and priority towards extensive research and development, which is facilitating the adoption of advanced antimicrobial susceptibility testing technologies. In February 2024, Visby Medical received a grant of USD 1.8 million to develop&nbsp;a fast and&nbsp;portable gonorrhoea diagnosis test&nbsp;that includes testing for antibiotic susceptibility. Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a US-based non-profit organization granted funds to a Boston-based company to develop a portable rapid polymerase chain reaction (PCR) diagnostic to identify the presence of Neisseria gonorrhoeae, a pathogen that causes gonorrhea, and its susceptibility to ciprofloxacin.
Future Market Scenario (2024-2031F)
1.&nbsp;The phenotyping of AST using flow cytometry, isothermal microcalorimetry, and digital imaging is becoming increasingly popular. Compared to standard growth-based AST, which can take 18-24 hours, can yield findings typically in 1-2 hours.
2.&nbsp;Whole genome sequencing is a genomic technique&nbsp;that may quickly identify genetic markers linked to antibiotic resistance. It is being investigated for AST. When contrasted with culture-based approaches, this could enable faster&nbsp;turnaround times.
3.&nbsp;Integrated diagnostic tools that are capable of AST and microbiological identification are becoming more common. These systems are designed to streamline the testing process and deliver fast results&nbsp;through data that will&nbsp;help with antibiotic selection.
4.&nbsp;Various regions&nbsp;and organizations, including the European Commission, European Food Safety Authority, European Medicines Agency, and European Centre for Disease Prevention and Control, are working to standardize and unify advancements in fast antimicrobial susceptibility testing.
Report Scope
&ldquo;Antimicrobial Susceptibility Testing&nbsp;Market&nbsp;Assessment, Opportunities and Forecast, 2017-2031F&rdquo;,&nbsp;is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global antimicrobial susceptibility testing market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.
<table>
<tbody>
<tr>
<td width="301">
Report Attribute
</td>
<td width="301">
Details
</td>
</tr>
<tr>
<td width="301">
Base Year of the Analysis
</td>
<td width="301">
2023
</td>
</tr>
<tr>
<td width="301">
Historical Period
</td>
<td width="301">
2017-2022
</td>
</tr>
<tr>
<td width="301">
Forecast Period
</td>
<td width="301">
2024-2031
</td>
</tr>
<tr>
<td width="301">
Projected Growth Rate
</td>
<td width="301">
CAGR of 6.07% between 2024 and 2031
</td>
</tr>
<tr>
<td width="301">
Revenue Forecast in 2031
</td>
<td width="301">
USD 6.43 billion
</td>
</tr>
<tr>
<td width="301">
Segments Covered
</td>
<td width="301">
Product, Type, Application, End-user
</td>
</tr>
<tr>
<td width="301">
Regions Covered
</td>
<td width="301">
North America, Europe, South America, Asia-Pacific, Middle East and Africa
</td>
</tr>
<tr>
<td width="301">
Key Companies Profile
</td>
<td width="301">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Biomeriux SA, Bio-Rad Laboratories Inc, HiMedia Laboratories, Alifax S.r.l. Italy, Becton Dickinson and Company, Creative Diagnostics, Resistell AG, Danaher Corporation, Thermo Fisher Scientific Inc, Merck KGaA
</td>
</tr>
<tr>
<td width="301">
Customization Scope
</td>
<td width="301">
15% free report customization with purchase
</td>
</tr>
<tr>
<td width="301">
Pricing and Purchase Options
</td>
<td width="301">
Avail the customized purchase options to fulfill your precise research needs
</td>
</tr>
<tr>
<td width="301">
Delivery Format
</td>
<td width="301">
PDF and Excel through email (subject to the license purchased)
</td>
</tr>
</tbody>
</table>
In the report,&nbsp;global antimicrobial susceptibility testing market&nbsp;has been segmented into the following categories:&nbsp;
<ul style="text-align: justify;">
<li>By Product
<ul>
<li>Manual Antimicrobial Susceptibility Testing Product</li>
<li>Automated Laboratory Instruments</li>
<li>Culture and Growth Media</li>
<li>Consumables</li>
</ul>
</li>
<li>By Type
<ul>
<li>Antibacterial Susceptibility Testing</li>
<li>Antifungal Susceptibility Testing</li>
<li>Antiparasitic Susceptibility Testing</li>
<li>Other Susceptibility Testing</li>
</ul>
</li>
<li>By Application
<ul>
<li>Clinical Diagnostics</li>
<li>Drug Discovery and Development</li>
<li>Epidemiology</li>
<li>Others</li>
</ul>
</li>
<li>By End-user
<ul>
<li>Hospitals</li>
<li>Diagnostic Centers</li>
<li>Pharmaceutical and Biotechnology Companies</li>
<li>Clinical Research Organizations</li>
<li>Others</li>
</ul>
</li>
<li>By Region
<ul>
<li>North America</li>
<li>Europe</li>
<li>Asia-Pacific</li>
<li>South America</li>
<li>Middle East and Africa</li>
</ul>
</li>
</ul>
Key Players Landscape and Outlook
Several medical device companies are flourishing in the antimicrobial susceptibility testing market by planning and adopting new strategies. They are complying with new strategic initiatives for antimicrobial susceptibility testing devices to increase their market presence. New agreements, contracts, acquisitions, mergers, investments, and partnerships are major ways through which they are trying to achieve higher market share.&nbsp;
In April 2023, Biomeriux SA and JMI labs established a six-year partnership&nbsp;to work together on projects aimed at assessing the effectiveness and expanding the potential of rapid and innovative microbiological diagnostics as crucial instruments in the fight against antibiotic resistance.&nbsp;
Key Players Operating in the Global Antimicrobial Susceptibility Testing Market are:
<ul style="text-align: justify;">
<li>Biomeriux SA</li>
<li>Bio-Rad Laboratories Inc</li>
<li>HiMedia Laboratories</li>
<li>Alifax S.r.l. Italy</li>
<li>Becton Dickinson and Company</li>
<li>Creative Diagnostics</li>
<li>Resistell AG</li>
<li>Danaher Corporation</li>
<li>Thermo Fisher Scientific Inc</li>
<li>Merck KGaA</li>
</ul>
Markets and Data report answers the following questions:
<ul style="text-align: justify;">
<li>What is the current and future market size of the product/service in question globally or specific to different countries?</li>
<li>How are the markets divided into different product/service segments and the market size and growth of each segment?</li>
<li>What is the market potential of different product segments and their investment case?</li>
<li>How are the markets predicted to develop in the future and what factors will drive or inhibit growth?</li>
<li>What is the business environment and regulatory landscape specific to the product/service?</li>
</ul>
If you can't find what you're searching for or have any custom requirements for global antimicrobial susceptibility testing market, you may approach our team at&nbsp;<a href="mailto:info@marketsandata.com">info@marketsandata.com</a>.

Global Antimicrobial Susceptibility Testing Market Assessment, Opportunities and Forecast, 2017-2031F

In clinical laboratories, antimicrobial susceptibility tests (ASTs) are used to identify which antibiotics or other antimicrobial medicines are likely to be successful against a certain microbe causing an illness and what dose is required to be effective.

FAQs

Industry Reports

Blogs

Case Studies

Industry News

Press Release

Infographics